OSLO, Norway, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Targovax (OSE: TRVX, or "the Company"), a clinical stage company developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management will present at the following conferences:
Nordic Life Science Days Date: 14 September 2016 Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP BD) Presentation time: 17:15 CET Venue: Waterfront Congress Center, Stockholm, Sweden
Sachs Associates: 16th Annual Biotech in Europe forum Date: 28 September 2016
Participant: Gunnar Gårdemyr (CEO)
Presentation time: 09:45 CET
Venue: Congress Center, Basel, Switzerland
Cutting Edge / Oslo Innovation Week Date: 18 October 2016 Participant: Peter Skorpil (VP BD) Presentation time: 11:40 CET Venue: Oslo Science Park, Oslo, Norway
Teknologirevolusjon innen kreftterapi Date: 26 October 2016
Participant: Magnus Jaderberg (CMO)
Presentation time: 11:20 CET
Venue: Oslo Cancer Cluster, Oslo, Norway
Presentations will be available to download at www.targovax.com following these events.
For further information, please contact:
Gunnar Gårdemyr, CEO Phone: +46 73 083 77 79 Email: email@example.com
Øystein Soug, CFO
Phone: +47 90 6565 25
Media and IR enquires:
Jan Petter Stiff - Crux Advisors (Norway) Phone: +47 995 13 891
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Arming the patient's immune system to fight cancer
Targovax (OSE: TRVX) is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.
ONCOS - 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.
These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.
In July 2016 the Company listed its shares on Oslo Axess, securing funding for further development of the Company's ongoing and planned trials
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Source: Targovax ASA